Evidence map›Paper›PMID 36839773›Full record

ReviewPharmaceutics2023

Aspects of Nanotechnology for COVID-19 Vaccine Development and Its Delivery Applications.

Pranav Kumar Prabhakar, Navneet Khurana, Manish Vyas, Vikas Sharma, Gaber El-Saber Batiha, Harpreet Kaur, Jashanpreet Singh, Deepak Kumar, Neha Sharma, Ajeet Kaushik and 1 more

Open access · goldAbstract readReview
In one paragraph

Review in Pharmaceutics, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed, 1 pooled it
5.6field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 1 synthesis or guideline pooled it, 29 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Review
  4. Review
  5. Review
  6. Review
  7. Review
  8. Article
  9. Review
  10. Article
  11. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 4 institutions in 3 countries.

Pranav Kumar PrabhakarSchool of Allied Medical Sciences, Lovely Professional University, Punjab 144411, India.ORCID 0000-0001-8130-1822
Navneet KhuranaSchool of Pharmaceutical Sciences, Lovely Professional University, Punjab 144411, India.ORCID 0000-0001-9899-4856
Manish VyasSchool of Pharmaceutical Sciences, Lovely Professional University, Punjab 144411, India.
Vikas SharmaSchool of Pharmaceutical Sciences, Lovely Professional University, Punjab 144411, India.
Gaber El-Saber BatihaDepartment of Pharmacology and Therapeutics, Faculty of Veterinary Medicine, Damanhour University, Damanhour 22511, Egypt.ORCID 0000-0002-7817-425X
Harpreet KaurSchool of Chemical Engineering and Physical Sciences, Lovely Professional University, Punjab 144411, India.
Jashanpreet SinghSchool of Chemical Engineering and Physical Sciences, Lovely Professional University, Punjab 144411, India.
Deepak KumarSchool of Chemical Engineering and Physical Sciences, Lovely Professional University, Punjab 144411, India.ORCID 0000-0002-6358-2453
Neha SharmaSchool of Pharmaceutical Sciences, Lovely Professional University, Punjab 144411, India.
Ajeet KaushikNanoBioTech Laboratory, Department of Environmental Engineering, Florida Polytechnic University, Lakeland, FL 33805, USA.ORCID 0000-0003-4206-1541
Raj KumarDepartment of Pharmaceutical Sciences, University of Nebraska Medical Sciences, Omaha, NE 68198, USA.ORCID 0000-0002-5497-9678
Lovely Professional University · INDamanhour University · EGFlorida Polytechnic University · USNebraska Medical Center · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Coronavirus, a causative agent of the common cold to a much more complicated disease such as "severe acute respiratory syndrome (SARS-CoV-2), Middle East Respiratory Syndrome (MERS-CoV-2), and Coronavirus Disease 2019 (COVID-19)", is a member of the coronaviridae family and contains a positive-sense single-stranded RNA of 26-32 kilobase pairs. COVID-19 has shown very high mortality and morbidity and imparted a significantly impacted socioeconomic status. There are many variants of SARS-CoV-2 that have originated from the mutation of the genetic material of the original coronavirus. This has raised the demand for efficient treatment/therapy to manage newly emerged SARS-CoV-2 infections successfully. However, different types of vaccines have been developed and administered to patients but need more attention because COVID-19 is not under complete control. In this article, currently developed nanotechnology-based vaccines are explored, such as inactivated virus vaccines, mRNA-based vaccines, DNA-based vaccines, S-protein-based vaccines, virus-vectored vaccines, etc. One of the important aspects of vaccines is their administration inside the host body wherein nanotechnology can play a very crucial role. Currently, more than 26 nanotechnology-based COVID-19 vaccine candidates are in various phases of clinical trials. Nanotechnology is one of the growing fields in drug discovery and drug delivery that can also be used for the tackling of coronavirus. Nanotechnology can be used in various ways to design and develop tools and strategies for detection, diagnosis, and therapeutic and vaccine development to protect against COVID-19. The design of instruments for speedy, precise, and sensitive diagnosis, the fabrication of potent sanitizers, the delivery of extracellular antigenic components or mRNA-based vaccines into human tissues, and the administration of antiretroviral medicines into the organism are nanotechnology-based strategies for COVID-19 management. Herein, we discuss the application of nanotechnology in COVID-19 vaccine development and the challenges and opportunities in this approach.

Indexed as

COVID-19diagnosismRNAmutationnanotechnologyvaccinevirus-vectored

Identifiers

PMID36839773
PMCPMC9960567
OpenAlexW4318480316

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.